Product Name: CDKL2 (478-493)
Product Number: PE-01BCN85
| Size: | 200 µg | Price: | 41.00 | |
| 1 mg | $US | 82.00 | ||
| 5 mg | 177.00 |
Peptide Name: CDKL2 (478-493)
Product Use: Services as a blocking peptide for use with the CDKL2-CT rabbit polyclonal antibody (Cat. No.: AB-NK261-1) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CLSDDSGADLPQMEHQH
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1883.04 Da
Peptide Purity Percent after Synthesis and Purification: >80
Product Use: Services as a blocking peptide for use with the CDKL2-CT rabbit polyclonal antibody (Cat. No.: AB-NK261-1) that is also available from Kinexus. The peptide sequence is located in the C-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CLSDDSGADLPQMEHQH
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1883.04 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CDKL2 pan-specific antibody (Cat. No.: AB-NK261-1)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CDKL2 pan-specific antibody (Cat. No.: AB-NK261-1)
Scientific Background: CDKL2 (KKIAMRE) is a protein-serine/threonine kinase of the CMGC group and CDKL family. It is likely that phosphorylation at Y161 is required for catalytic activity and phosphorylation at Y15 is inhibitory based on homology with other CDK's. It is induced when cells are stimulated with epidermal growth factor. It may play a role in signal transduction and differentiation. It has been found to have a role in memory and learning. CDKL2 may be an oncoprotein (OP). It has been identified as a novel potent promoter for epithelial-mesenchymal transition and breast cancer progression (PubMed: 25333262). CDKL2 stimulated primary tumour formation and metastasis in a breast cancer xenograft model. It is expressed at significantly higher levels mesenchymal human breast cancer cell lines than in epithelial lines, and its over-expression/amplification in human breast cancers is correlated with shorter disease-free survival.
© Kinexus Bioinformatics Corporation 2017